Company Performance - Neuphoria Therapeutics Inc. (NASDAQ:NEUP) experienced a significant stock price drop of 67.18%, closing at $5.05, due to the failure of its AFFIRM-1 Phase 3 trial for BNC210, which did not meet its primary and secondary endpoints. The company plans to conduct a strategic review of its portfolio and operations [1] - AlphaVest Acquisition Corp Unit (NASDAQ:ATMVU) saw a 41.05% decline in its stock price to $12.97, potentially linked to investor sentiment surrounding its merger agreement with AMC Corporation, highlighting the speculative nature of SPACs [2] - Cycurion, Inc. (NASDAQ:CYCU) faced a 34.51% decrease in stock price to $0.16 after receiving a Delisting Determination Letter from Nasdaq, indicating challenges ahead for the company and impacting investor confidence [3] - SMX (Security Matters) Public Limited Company (SMX) experienced a 32.03% decline in stock price to $0.78, with market performance possibly reacting to undisclosed operational updates or industry trends [4] - American Rebel Holdings, Inc. (NASDAQ:AREB) saw a 29.91% reduction in stock price to $1.31, despite securing a distribution placement for its American Rebel Light Beer, indicating broader economic factors affecting consumer cyclical sectors [5] Market Trends - Recent market movements illustrate the volatile nature of stock prices, influenced by company-specific news, industry trends, and broader economic conditions, prompting investors and stakeholders to adjust their strategies accordingly [6]

AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that the AFFIRM-1 Phase 3 trial of BNC210 for the acute treatment of social anxiety disorder (SAD) did not meet its primary ...

Core Insights - Neuphoria Therapeutics Inc. is making steady progress in its clinical pipeline, particularly with its lead program BNC210 for Social Anxiety Disorder and partnered asset MK-1167 for Alzheimer's disease [2][6] Clinical Programs - BNC210 is currently enrolling in the AFFIRM-1 Phase 3 study for Social Anxiety Disorder, with topline data expected in Q3 2025 [2][7] - MK-1167 is in a Phase 2 trial led by Merck for Alzheimer's disease, showing continued momentum [2][4] - A Phase 2b trial (SYMPHONY) for BNC210 in PTSD is being planned following a successful End-of-Phase 2 meeting with the FDA [7] Product Details - BNC210 is a first-of-its-kind oral therapy designed to treat social anxiety disorder and PTSD without sedation, cognitive impairment, or addiction potential [4][7] - The drug acts as a selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, aiming to restore neurotransmitter balance [4] Financial Outlook - The company has a cash runway extending into Q3 2026, supporting ongoing clinical trials and development efforts [6]